Jacobio Pharmaceuticals Group Co., Ltd. (JBPHF)

Market Cap	469.86M -28.6%
Revenue (ttm)	108.75M +266.9%
Net Income	75.61M
EPS	0.10
Shares Out	n/a
PE Ratio	7.73
Forward PE	13.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	900
Open	0.7552
Previous Close	0.7234
Day's Range	0.7552 - 0.7552
52-Week Range	0.5955 - 1.1000
Beta	0.34
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 24, 2026

About JBPHF

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People’s Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic mal...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 207
• Stock Exchange: OTCMKTS
• Ticker Symbol: JBPHF

Financial Performance

In 2025, JBPHF's revenue was 53.53 million, a decrease of -65.62% compared to the previous year's 155.71 million. Losses were -145.98 million, -6.25% less than in 2024.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 9, 2026

Data Sources Report a data error